产碳青霉烯酶肺炎克雷伯菌导致的复发性肺炎治疗期间出现的多黏菌素耐药性。
Emergence of colistin resistance during treatment of recurrent pneumonia caused by carbapenemase producing Klebsiella pneumoniae.
机构信息
Laboratory of Clinical Microbiology, Antwerp University Hospital, Edegem, Belgium; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
出版信息
Diagn Microbiol Infect Dis. 2019 Aug;94(4):407-409. doi: 10.1016/j.diagmicrobio.2019.02.014. Epub 2019 Feb 21.
A 60-year-old woman received meropenem/colistin treatment for bilateral pneumonia caused by a ST15 carbapenemase producing Klebsiella pneumoniae. The patient recovered but re-infection with the same (ST15), but now colistin-resistant K. pneumoniae, occurred. The molecular mechanism of the emerged colistin resistance was identified as mgrB gene modification by insertion element (IS) IS903B.
一位 60 岁女性因产 ST15 碳青霉烯酶肺炎克雷伯菌导致双侧肺炎接受美罗培南/黏菌素治疗。患者康复，但出现相同（ST15）但现在对黏菌素耐药的肺炎克雷伯菌再感染。新出现的黏菌素耐药的分子机制被鉴定为 mgrB 基因通过插入元件（IS）IS903B 的修饰。
Zotero 插件